Mechanism: Mitochondrial tRNA mutations activate CDK5 via calcium, leading to lamin A/C phosphorylation, nuclear envelope dysfunction, and chromatin leakage. Readout: Readout: Inhibiting CDK5 or providing wild-type tRNA restores nuclear integrity, reduces SASP, and increases lifespan by 25% without altering ROS levels.
Hypothesis
We propose that specific point mutations in mitochondrial tRNA genes activate a CDK5‑dependent kinase cascade that phosphorylates lamin A/C at serine‑22, leading to nuclear envelope softening and chromatin leakage, independent of the classic ROS‑JNK retrograde pathway.
Mechanistic Rationale
- mtDNA tRNA dysfunction reduces mitochondrial translation efficiency, causing a buildup of uncharged tRNAs that activate the mitochondrial unfolded protein response (mtUPR) and subsequently the cytosolic kinase CDK5 via calcium release from the ER‑mitochondria interface.
- CDK5 phosphorylates lamin A/C, weakening its interaction with LAP1 and emerin, which destabilizes the lamina and promotes extrusion of chromatin fragments (CCFs) and cGAS‑STING activation.
- This pathway can be triggered even when ROS levels are modest, explaining why low‑heteroplasmy mtDNA mutations shorten lifespan without overt oxidative stress.
Testable Predictions
- Prediction 1: In aged mice harboring the pathogenic mtDNA tRNA^Leu(UUR) m.3243A>G mutation (low heteroplasmy), pharmacological inhibition of CDK5 (e.g., roscovitine) will restore lamin A/C phosphorylation levels to youthful baselines and reduce CCF extrusion, despite persistent mtDNA mutation load.
- Prediction 2: Mitochondrial‑targeted expression of a wild‑type tRNA^Leu(UUR) gene (allotopic expression) will suppress CDK5 activation and lamin A/C pathology, rescuing nuclear morphology without altering ROS‑JNK signaling.
- Prediction 3: Cells expressing a phospho‑deficient lamin A/C S22A mutant will be resistant to mtDNA tRNA‑induced nuclear envelope defects, showing diminished SASP secretion even when mtDNA mutation load is high.
Experimental Approach
- Generate a knock‑in mouse model carrying the m.3243A>G mtDNA mutation at ~15 % heteroplasmy in heart and liver.
- Treat cohorts with either CDK5 inhibitor, vehicle, or allotopic tRNA^Leu(UUR) AAV9 for 3 months.
- Assess lamin A/C phosphorylation (Western blot with phospho‑specific S22 antibody), nuclear envelope morphology (EM), CCF flow cytometry, and SASP cytokine profiling.
- Include ROS measurements (MitoSOX) to confirm that phenotypic rescue occurs without significant ROS reduction.
Falsification
If CDK5 inhibition or tRNA allotopic expression fails to improve lamin A/C integrity or SASP despite correcting the mtDNA mutation, or if lamin A/C S22A does not rescue the phenotype, the hypothesis would be falsified, indicating that mtDNA tRNA dysfunction acts through alternative retrograde mechanisms.
Broader Impact
Demonstrating a direct mtDNA‑to‑lamina signaling axis would shift focus from global ROS scavenging to precise kinase‑targeted interventions, offering a mechanistic bridge between mitochondrial genome integrity and nuclear aging phenotypes.
References [1] https://pubmed.ncbi.nlm.nih.gov/32001510/ [2] https://www.science.org/doi/10.1126/science.adf2034 [3] https://doi.org/10.1038/s41598-018-24290-6 [4] https://academic.oup.com/nar/article/50/17/9948/6696852 [5] https://english.cas.cn/newsroom/research-news/202602/t20260210_1150422.shtml [6] https://www.fightaging.org/archives/2020/02/a-discussion-of-recent-work-on-allotopic-expression-of-mitochondrial-genes-at-the-sens-research-foundation/ [7] https://pubmed.ncbi.nlm.nih.gov/35203698/
Comments
Sign in to comment.